New Edition of NABCO Breast Cancer Resource List Is Now Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

NEW YORK--The National Alliance of Breast Cancer Organizations (NABCO) has just published the 1996-1997 edition of the NABCO Breast Cancer Resource List, made possible through an educational grant from Glaxo Wellcome Inc

NEW YORK--The National Alliance of Breast Cancer Organizations(NABCO) has just published the 1996-1997 edition of the NABCOBreast Cancer Resource List, made possible through an educationalgrant from Glaxo Wellcome Inc.

At more than 75 pages, it is NABCO's most comprehensive breastcancer resource guide to date. The booklet includes educationaland resource information for both the lay public and health careprofessionals, as well as a list of 350 breast cancer supportgroups nationwide. Many of the more than 2,000 listed publications(books, brochures, and videos) are available free or at low cost.

To obtain a copy, please send a self-addressed mailing label anda $3.00 check to NABCO, 9 East 37th Street, New York, NY 10016.Please indicate if you prefer the waiting room version markedwith the legend "Display Copy."

Articles in this issue
Routine Office Endometrial Biopsies and Ultrasound Screening Are Not Recommended for Breast Cancer Patients Receiving Tamoxifen
AHCPR to Fund Analysis of the Impact of Managed Care's Growth
Avon Funds Breast Cancer Awareness Program for Orthodox Jewish Women
ASTRO Honors Two Members With Gold Medal and Bestows Honorary Memberships on Two
Friends of Cancer Research Campaign
Four Cancer Chemoprevention Trials Seek Subjects
Overall US Cancer Mortality Rate Falls for the First Time
Four Scenarios Describe Impact of Cancer Research in 2015
New Edition of NABCO Breast Cancer Resource List Is Now Available
Changes in Congressional Committee Chairmen Could Impact Oncologists
Growth Factor in Elderly ALL Patients Improves Outcome
Human Genetic Map Goes On-Line
Study to Explore Smoking Cessation After a Cancer Diagnosis
Novantrone Gets FDA Nod for Use in Advanced Prostate Cancer
New Cancer Programs, Office of Cancer Survivorship Announced
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Ariana Pelosci
August 14th 2025
Article

Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
August 12th 2025
Article

Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Enhances DCIS Risk Stratification Beyond Clincopathology

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Ariana Pelosci
July 29th 2025
Article

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.